Aurinia Pharmaceuticals (FRA:IKAP) Insider Ownership: 0.00 % (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:IKAP Aurinia Pharmaceuticals Inc FRA:IKAP
80 GF Score
Price €14.66
GF Value €12.72
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Aurinia Pharmaceuticals Insider Ownership?

Aurinia Pharmaceuticals FRA:IKAP +0.48% 80 Insider Ownership is 0.00 % as of Sep. 21, 2026. GuruFocus rates FRA:IKAP with a GF Score™ of 80/100 and a GF Value™ of €12.72 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Aurinia Pharmaceuticals's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Aurinia Pharmaceuticals's Institutional Ownership is 20.61%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Aurinia Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 90.58%.

Aurinia Pharmaceuticals Insider Ownership Historical Data

* Premium members only.

The historical data trend for Aurinia Pharmaceuticals's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aurinia Pharmaceuticals Insider Ownership Chart

Aurinia Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Insider Ownership
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aurinia Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Insider Ownership Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
FRA:IKAP
80GF Score
Aurinia Pharmaceuticals Inc FRA:IKAP
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aurinia Pharmaceuticals Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 0.00 % mean?
Aurinia Pharmaceuticals (FRA:IKAP) has a Insider Ownership of 0.00 % as of Sep. 21, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Aurinia Pharmaceuticals and its competitors.
Is Aurinia Pharmaceuticals' Insider Ownership too high?
Aurinia Pharmaceuticals' current Insider Ownership is 0.00 %. Overall, Aurinia Pharmaceuticals has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aurinia Pharmaceuticals' Insider Ownership compare to PVLA and SRPT?
Aurinia Pharmaceuticals' Insider Ownership of 0.00 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Aurinia Pharmaceuticals and its competitors. Aurinia Pharmaceuticals's current Insider Ownership is 0.00 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurinia Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Aurinia Pharmaceuticals (FRA:IKAP) is currently considered Modestly Overvalued. The stock's GF Value™ is €12.72, compared to a current price of €14.66 — trading 15.3% above its estimated fair value. The current Insider Ownership is 0.00 %. Aurinia Pharmaceuticals' overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Aurinia Pharmaceuticals (FRA:IKAP), the current Insider Ownership is 0.00 % as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aurinia Pharmaceuticals (FRA:IKAP) Overvalued in 2026?

Based on GuruFocus' analysis, Aurinia Pharmaceuticals stock appears to be overvalued. The current stock price of €14.66 is trading 15.3% above its estimated GF Value™ of €12.72. GuruFocus considers Aurinia Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for FRA:IKAP:

  • Insider Ownership: 0.00 %
  • GF Value™: €12.72 vs. price of €14.66 (15.3% above fair value)
  • GF Score™: 80/100 with 5 warning signs

No single metric tells the full story. See the FRA:IKAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aurinia Pharmaceuticals Business Description

Other Exchanges AUPH:USAIKAP:Germany
Address 14315 - 118 Avenue, Suite 140, Edmonton, AB, CAN, T5L 4S6
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
80GF Score

Get the complete analysis for FRA:IKAP

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.66
Price
€12.72
GF Value